The present invention relates to the use of nanodiamonds as drugs generating free radicals, in particular for treating tumors. The invention is based on generating free radicals on the surface of the nanodiamonds when they are exposed to radiation, for example ionizing radiation. In order to increase the effectiveness of the nanodiamonds, the nanodiamonds can be complexed with a radiosensitizing agent, such as a chemical molecule or an interfering RNA targeting a repairing gene.

A compound including a poly-oxygenated metal hydroxide comprising a clathrate containing oxygen gas O.sub.2(g) molecules, and CBD.

Described herein are tolerogenic compositions for use in a method of treatment for multiple sclerosis (MS) in a MS subject exhibiting T-cell autoreactivity against an endogenous epitope corresponding to a T-cell epitope comprising a sequence of at least 8 consecutive amino acid residues differing from a sub-sequence of SEQ ID NO: 5 by 0-2 residue substitutions, deletions and/or insertions, or the composition comprising a nucleic acid encoding said therapeutic T-cell epitope. Also described are methods for determining antigen-specific T-cell activation in a test subject, comprising providing a test sample derived from the test subject comprising viable T-cells; determining antigen-specific activation of the T-cells of the test sample in vitro in response to a test antigen comprising a T-cell epitope; and comparing the determined antigen-specific activation to a relevant reference to determine the degree of MS-related autoimmunity in the test subject.

The invention relates to compositions for administering zinc, including nutritional supplement compositions, comprising ?-polyglutamic acid, a zinc salt, and a gastro-resistant material for use as a dietary supplement to provide zinc to persons desiring or in need thereof, and methods for preparing such compositions as solid dosage forms such as tablets and capsules, and as liquid dosage forms.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Aspects of the invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized storage stable composition. In some instances, the lyophilized compositions include one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition in a subject.

Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.

Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.

A combination therapy comprising a MEK inhibitor, a PD-1 or PD-L1 inhibitor, and a taxane is provided for the treatment of cancer, such as triple negative breast cancer.